Squarepoint
TNGX icon

Squarepoint’s Tango Therapeutics TNGX Stock Holding History

Squarepoint’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$736K Sell
23,558
-155,357
-87% -$3.84M ﹤0.01% 3138
2026
Q1 		$3.74M Buy
178,915
+4,979
+3% +$69.3K ﹤0.01% 1725
2025
Q4 		$1.54M Buy
+173,936
New +$1.5M ﹤0.01% 2246
2025
Q1 		– Sell
-12,843
Closed -$39.7K – 5419
2024
Q4 		$39.7K Buy
+12,843
New +$59.6K ﹤0.01% 4877
2024
Q3 		– Sell
-14,158
Closed -$121K – 4704
2024
Q2 		$121K Sell
14,158
-51,040
-78% -$394K ﹤0.01% 3758
2024
Q1 		$518K Sell
65,198
-34,610
-35% -$371K ﹤0.01% 3026
2023
Q4 		$988K Buy
+99,808
New +$866K ﹤0.01% 2536
2023
Q3 		– Sell
-40,316
Closed -$134K – 4254
2023
Q2 		$134K Sell
40,316
-52,422
-57% -$189K ﹤0.01% 3310
2023
Q1 		$366K Buy
+92,738
New +$538K ﹤0.01% 2468
2022
Q4 		– Sell
-27,979
Closed -$101K – 3601
2022
Q3 		$101K Buy
+27,979
New +$119K ﹤0.01% 2794
2022
Q2 		– Sell
-83,555
Closed -$633K – 3380
2022
Q1 		$633K Buy
+83,555
New +$724K ﹤0.01% 1872

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Squarepoint's TNGX Position: Q2 2026 in Review

Squarepoint reduced its Tango Therapeutics (TNGX) stake by 87% in Q2 2026, selling an estimated $3.84M and leaving 23,558 shares worth $736K. The position accounts for ﹤0.01% of the portfolio, ranked #3138.

Squarepoint first reported a position in TNGX in Q1 2022 and has held it in 11 quarters since. The position peaked at $3.74M in Q1 2026. 249 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • Squarepoint held 23,558 shares of Tango Therapeutics worth $736K as of Q2 2026.
  • Squarepoint sold 155,357 Tango Therapeutics shares in Q2 2026, an estimated $3.84M.
  • Tango Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3138 holding.
  • Squarepoint first reported a position in Tango Therapeutics in Q1 2022 and has held it in 11 quarters since.
  • Squarepoint's Tango Therapeutics position peaked at $3.74M in Q1 2026.
  • 249 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.